Press release
Treatment for rare, paediatric growth hormone deficiency recommended by NICE for use on the NHS
December 22, 2022Medical Communications
Walton Oaks, 22 December 2022 – Pfizer Ltd today announces that the National Institute for Health and Care Excellence (NICE) …
OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas
December 22, 2022Business Services
Nantes, France – December 22,
Innovative Antibody Discovered by RQ Bio Enters Clinic as Part of Antibody Combination Within 12 Months of Discovery
December 21, 2022Medical Communications
LONDON, UK, 21st December 2022 — RQ Bio announces that the first of its discovered monoclonal antibodies to prevent COVID-19 …
Sosei Heptares’ Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
December 21, 2022Business Services
Tokyo, Japan and Cambridge, UK, 21 December 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
December 21, 2022Business Services
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that it …
NICE EXTENDS USE OF ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) TO EARLIER IN THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
December 20, 2022Business Services
Uxbridge and London, UK – (20 December 2022) – Daiichi Sankyo UK Limited and AstraZeneca UK Limited today welcome the …
Psoriasis community comes together and calls for collective action to help improve the lives of people with psoriasis
December 19, 2022Business Services
Slough, UK, 15 December 2022 – UCB, a global biopharmaceutical company, has announced results from the Epicensus programme, published in …
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
December 19, 2022Business Services
Tokyo, Japan and Cambridge, UK, 16 December 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) announces it has entered …
Alchemab Therapeutics and Medicines Discovery Catapult awarded £1.7 million grant from Innovate UK to accelerate development of disease-modifying therapy for Huntington’s Disease
December 19, 2022Business Services
Cambridge, UK. December 16 2022 – Alchemab Therapeutics, a biotechnology company unlocking new therapies from within the immune system, today …
FlyPharma Conference Middle East: New location announced
December 14, 2022Business Services
FlyPharma Conferences are pleased to announce an exciting new addition to its event portfolio: FlyPharma Middle East. Taking place in …
PPAs – Ready to make a long-term commitment to zero carbon?
December 14, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Energy, sustainability
As an industry that consumes a large amount of energy, the pressure is on for the pharmaceutical sector to achieve …
Interactions with the Agencies During Drug Development
April 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cambridge, NDA, drug development
NDA would like to invite you to join Professor Steffen Thirstrup, Director NDA Advisory Board, formerly Division Head at the Danish Medicines …
Woodley Equipment Company Acquires Blinded Diagnostics
December 11, 2018Research and Development POCT, Point of Care Testing, clinical research, clinical trials, point-of-care testing
HORWICH, BOLTON Dec1 2018: Woodley Equipment Company Inc, a leading global supplier of rental equipment for use in Clinical Trials …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
